Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: The cancer-DACUS study

noticia |

Napolitano M., Saccullo G., Malato A., Sprini D., Ageno W., Imberti D., Mascheroni D., Bucherini E., Gallucci P., D’Alessio A., Prantera T., Spadaro P., Rotondo S., Di Micco P., Oriana V., Urbano O., Recchia F., Ghirarduzzi A., Lo Coco L., Mancuso S., Casuccio A., Rini G.B., Siragusa S.

Journal of Clinical Oncology 2014 32:32 (3607-3612)

Purpose: We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of anticoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs. Patients and Methods: Patients with active cancer and a first episode of DVT treated with low molecular weight heparin (LMWH) for 6 months were eligible. Patients were managed according to RVT findings: those with RVT were randomly assigned to continue LMWH for an additional 6 months (group A1) or to discontinue it (group A2), and patients without RVT stopped LMWH (group B). The primary end point was recurrent venous thromboembolism (VTE) during the 1 year after discontinuation of LMWH…(ver más)

Valora esta noticia

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading...